Pediatric Brain Tumors Global Market Report 2025

The pediatric brain tumor market size has grown strongly in recent years. It will grow from $1.4 billion in 2024 to $1.5 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to the increasing incidence of pediatric brain tumors, the rise of emerging economies, growing investment in research and development, the increasing demand for advanced diagnostic technology, and the global rise in pediatric tumor cases.

The pediatric brain tumor market size is expected to see strong growth in the next few years. It will grow to $1.83 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to the advancements in precision medicine, molecular profiling, targeted therapy, rising healthcare infrastructure, and extended insurance coverage. Major trends include improvements in magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scanning technologies, the increasing use of genetic and molecular profiling, the development of targeted therapies, the introduction of immunotherapies, and the rise of minimally invasive surgical techniques.

The increasing demand for personalized medicine is expected to drive growth in the pediatric brain tumors market. Personalized medicine is a healthcare approach that tailors treatments and medical decisions to an individual’s genetic profile, lifestyle, and specific health needs. The demand for personalized medicine is rising due to advancements in genetic research, improved diagnostic tools, and the potential for more precise and effective treatments. By customizing therapies based on a child's tumor type, genetic mutations, and response patterns, personalized medicine enhances treatment outcomes while minimizing damage to healthy tissue and reducing side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based healthcare organization, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. As a result, the growing demand for personalized medicine is fueling the expansion of the pediatric brain tumor market.

Companies in the pediatric brain tumors market are focusing on developing innovative treatments such as type II RAF inhibitors to improve targeted therapies and enhance patient outcomes. Type II RAF inhibitors work by selectively inhibiting RAF kinases, particularly those with mutations that promote tumor growth. These inhibitors target abnormal RAF protein structures found in certain pediatric low-grade glioma (pLGG) subtypes, effectively disrupting faulty signaling pathways that contribute to tumor cell proliferation and survival. For example, in April 2024, Day One Biopharmaceuticals, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for OJEMDA (tovorafenib) for the treatment of relapsed or refractory pediatric low-grade glioma (pLGG) in patients aged six months and older with specific BRAF alterations. This approval marks OJEMDA as the first FDA-approved therapy targeting BRAF fusions or mutations in this patient group. The decision was based on data from the FIREFLY-1 clinical trial, which demonstrated an overall response rate of 51%, highlighting the drug’s efficacy in treating pediatric brain tumors that have not responded to prior treatments.

In July 2024, Ipsen, a France-based biopharmaceutical company, entered into a partnership with Day One Biopharmaceuticals to commercialize tovorafenib for pediatric low-grade glioma (pLGG) outside the United States. Through this collaboration, Ipsen will manage the regulatory and commercial aspects of tovorafenib’s global expansion. Day One Biopharmaceuticals, a US-based company specializing in treatments for childhood brain tumors, developed OJEMDA to address the unmet medical needs of pediatric patients.

Major players in the pediatric brain tumors market are AbbVie Inc., Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Ipsen Pharma, Novocure, Blueprint Medicines, Karyopharm Therapeutics Inc., Renaissance Pharma, Servier Laboratories, Matica Biotechnology, Curis Inc., Oncoheroes Biosciences, Treovir Inc., Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., and Seattle Children's Therapeutics.

North America was the largest region in the pediatric brain tumors market in 2024. The regions covered in pediatric brain tumors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pediatric brain tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Pediatric brain tumors are abnormal cell growths in the brain or central nervous system (CNS) of children, which can be either benign (non-cancerous) or malignant (cancerous). These tumors may develop in different areas of the brain or spinal cord, with treatment aimed at shrinking or removing the tumor, alleviating symptoms, and preserving cognitive and motor functions to support the child's long-term health and development.

The primary types of pediatric brain tumors include gliomas, mixed neuronal-glial tumors, embryonal tumors, choroid plexus papilloma or carcinoma, tumors arising from non-neuroepithelial tissue, and meningeal tumors. Gliomas are the most common type, originating from glial cells and requiring aggressive treatment due to their infiltrative growth and high recurrence potential. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, while diagnostic methods involve imaging techniques, biopsy, neurological exams, and lumbar puncture. Pediatric brain tumors can occur in various age groups, including infants, toddlers, children, and adolescents, and are managed in settings such as hospitals and clinics, medical research centers, academic institutes, and others.

The pediatric brain tumor market research report is one of a series of new reports that provides pediatric brain tumor market statistics, including the pediatric brain tumor industry global market size, regional shares, competitors with the pediatric brain tumor market share, detailed pediatric brain tumor market segments, market trends, and opportunities, and any further data you may need to thrive in the pediatric brain tumor industry. This pediatric brain tumor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pediatric brain tumor market consists of revenues earned by entities providing services such as neuro-oncology care, rehabilitation services, psychosocial support, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The pediatric brain tumor market also includes sales of chemotherapy drugs, surgical instruments, and radiation therapy equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.